PULMONX CORP

Company Overview

Pulmonx (LUNG) is a California-based medical device company focused on bronchoscopic solutions for severe emphysema, principally through its Zephyr Valve platform. Recent results (Q2 2025) show accelerating procedure-driven revenue growth ($23.9M, +14.8% y/y; H1 revenue $46.4M, +17.1% y/y) with healthy gross margins near 72% but continued net losses (Q2 net loss $15.2M; H1 net loss $29.6M). The business is expanding its direct U.S. commercial footprint (91% of revenue in direct markets), investing in sales and marketing, manufacturing scale-up, and ongoing clinical programs (CONVERT II for AeriSeal). Liquidity includes ~$84.2M cash and ~$37.1M outstanding debt with a CIBC term loan through Oct 2027; management expects continued investment and near‑term net losses.

Executive Compensation Practices

Given Pulmonx’s growth-stage medical-device profile, pay is likely weighted toward equity and milestone-linked long‑term incentives (options/RSUs) that reward adoption of the Zephyr Valve, procedure volume growth, and market expansion. Short‑term cash bonuses, if material, will probably be tied to revenue/procedure targets, gross‑margin improvement as manufacturing scales, and commercial KPIs such as sales hires and unit placements rather than GAAP profitability given persistent net losses. Clinical and regulatory milestones (CONVERT II outcomes, reimbursement/coverage decisions) are natural triggers for performance vesting or one‑time awards. Cash conservation and existing debt covenants may constrain large cash payouts, increasing reliance on equity compensation and retention grants to recruit and retain sales leadership.

Insider Trading Considerations

Insiders will likely hold significant equity from option/RSU grants and may use scheduled 10b5‑1 plans to sell for diversification or tax needs; monitor Form 4s for deviations from typical patterns. Trades are often timed — legally or via plans — around discrete, market‑moving events for Pulmonx: quarterly results, Zephyr Valve procedure adoption data, CONVERT II trial milestones, Medicare/private payer coverage updates, and manufacturing/scale announcements. Because the company remains loss‑making with a finite runway and outstanding debt, insider transactions ahead of financing announcements or dilution events warrant extra scrutiny. Standard blackout periods around earnings and clinical disclosures, plus Section 16 reporting rules, will affect visible insider activity.